Saturday 17 October 2026
Export MYGN’s income statement to Excel — free account
Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.98
0.37
−8.51%
Follow MYGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.67 | 0.51 | 0.69 | 0.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(65.22) | (26.86) | 53.73 | 31.90 | |
P/B ratio |
1.78 | 1.25 | 1.55 | 1.81 | |
Price to Tangible BV |
4.60 | 2.92 | 3.49 | 4.26 | |
EV/Sales |
0.75 | 0.58 | 0.73 | 0.86 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
78.73 | 198.73 | 332.88 | (321.19) | |
EV/FCF |
(42.69) | (20.56) | (23.41) | (18.45) | |
Quick Ratio |
1.72 | 1.91 | 1.98 | 1.78 | |
Current Ratio |
2.21 | 2.40 | 2.49 | 2.33 | |
Net Debt/EBITDA |
(0.21) | 0.32 | (3.09) | 2.42 | |
Debt/Assets |
18.89% | 17.86% | 16.97% | 16.41% | |
Debt/Equity |
0.40 | 0.36 | 0.33 | 0.32 | |
Asset Turnover |
1.23 | 0.99 | 0.95 | 0.91 | |
Operating CF/Net income |
0.19 | 0.46 | (1.34) | (0.77) | |
Capex/Depreciation |
(0.26) | (0.36) | (0.39) | (0.49) | |
Interest Coverage |
(9.49) | (7.49) | (1.30) | (6.13) | |
Research and Development Expense of Revenue |
13.11% | 13.52% | 12.15% | 13.71% | |
Selling, General and Administrative Expense of Revenue |
73.89% | 67.76% | 59.25% | 67.53% | |
Intangible Assets out of Total Assets |
0.29 | 0.29 | 0.29 | 0.29 | |
Share Based Compensation of Revenue |
3.78% | 3.24% | 1.33% | 5.93% | |
Graham Net Nets |
(0.08) | (0.06) | (0.01) | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(20.84%) | (95.56%) | (64.08%) | (59.90%) | |
Free Cash Flow Yield |
(2.62%) | (5.50%) | (4.50%) | (5.69%) | |
Revenue per Share |
2.01 | 2.14 | 2.27 | 2.21 | |
Operating CF per Share |
(0.09) | (0.17) | 0.11 | 0.23 | |
Capex per Share |
(0.03) | (0.07) | (0.06) | (0.07) | |
Free Cash Flow per Share |
(0.12) | (0.24) | 0.05 | 0.16 | |
Cash per Share |
1.22 | 1.33 | 1.62 | 1.56 | |
Shareholders Equity per Share |
3.21 | 3.60 | 3.97 | 4.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.21 | 3.60 | 3.97 | 4.00 | |
Free Cash Flow |
(11.50) | (22.20) | 4.60 | 14.90 | |
Working Capital |
158.30 | 182.60 | 198.80 | 196.80 | |
Capital Expenditures |
(3.20) | (6.50) | (6.00) | (6.20) | |
Net Current Asset Value |
(46.00) | (23.50) | (6.00) | (10.50) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
123.25 | 122.10 | 118.25 | 121.85 | |
Average Payables |
30.65 | 30.35 | 31.15 | 30.70 | |
Average Inventory |
29.65 | 28.10 | 29.05 | 28.90 | |
Average Assets |
658.10 | 839.90 | 867.10 | 904.70 | |
Average Common Equity |
346.00 | 521.15 | 534.55 | 552.25 |
Columns are period end dates